At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 95 enrolled
Drug / intervention
No Study Drug was Administered in this Studyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Site, Prospective, Longitudinal, Cohort Study Measuring Cerebrospinal Fluid-Mutant Huntingtin Protein in Patients With Huntington's Disease
In Brief
A Phase 1 clinical trial evaluating No Study Drug was Administered in this Study for Huntington's Disease. Completed, enrolled 95 participants across 15 sites in 4 countries.
Detailed Summary
The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's Disease (HD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington's Disease
CountriesCanada, Germany, United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartDec 2018
Primary CompletionMay 2021
Study CompletionMay 2022
TodayJul 2026
First PostedSep 11, 2018
Enrollment StartDec 5, 2018
Primary CompletionMay 7, 2021
Study CompletionMay 7, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.8 years ago
Interventions
No Study Drug was Administered in this Studyother
No study drug was administered in this study